Skip to main content

Table 1 Baseline characteristics of the keloids group and the control group

From: The association between keloid and osteoporosis: real-world evidence

Variables Keloid P value
  Yes No  
  N=8597 N=34,388  
Osteoporosis patients, n (%) 178 (2.07) 587 (1.71) < 0.05
Period of developing osteoporosis median (IQRa), years 3.0 (1.2–5.7) 6.7 (4.1–10.2) < 0.001
Mean age of osteoporosis (SDb), years 56.3 (14.0) 65.5 (14.8) < 0.001
Age mean (SDb), years 34.6 (13.5) 34.7 (13.7) 0.299
Age group, n (%)
 20–29 4302 (50.04) 17,208 (50.04)  
 30–39 1939 (22.55) 7756 (22.55)  
 40–49 1194 (13.89) 4776 (13.89)  
 50–59 617 (7.18) 2468 (7.18)  
 60–69 309 (3.59) 1236 (3.59)  
> 70 236 (2.75) 944 (2.75) 1.000
Sex, n (%)
 Males 3235 (37.63) 12,940 (37.63)  
 Females 5362 (62.37) 21,448 (62.37) 1.000
Charlson Comorbidity Index, n (%)
 0 2494 (29.01) 16,286 (47.36)  
 1 3963 (46.10) 13,710 (39.87)  
 2 1389 (16.16) 3018 (8.78)  
 ≥3 751 (8.74) 1374 (4.00) < 0.001
Co-morbidity, n (%)
 Hyperlipidemia 1771 (20.60) 4197 (12.20) < 0.001
 Hypertension 1513 (17.60) 3818 (11.10) < 0.001
 Diabetes mellitus 1049 (12.20) 2533 (7.37) < 0.001
 Chronic liver disease 2186 (25.43) 4947 (14.39) < 0.001
 Chronic kidney disease 568 (6.61) 1352 (3.93) < 0.001
 Chronic pulmonary disease 2887 (33.58) 8370 (24.34) < 0.001
 Hyperthyroidism 643 (7.48) 1424 (4.14) < 0.001
 Hyperparathyroidism 19 (0.22) 35 (0.10) 0.005
 Stroke 262 (3.05) 530 (1.54) < 0.001
 Depression 1066 (12.40) 2274 (6.61) < 0.001
 Alcohol attributed disease 232 (2.70) 632 (1.84) < 0.001
 Obesity 227 (2.64) 591 (1.72) < 0.001
 Tobacco use disorder 65 (0.76) 122 (0.35) < 0.001
  1. a IQR Interquartile range; b SD Standard deviation;